Home Cart Sign in  
Chemical Structure| 545380-34-5 Chemical Structure| 545380-34-5

Structure of QNZ
CAS No.: 545380-34-5

Chemical Structure| 545380-34-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

QNZ (EVP4593) shows strong inhibitory effects on NF-κB transcriptional activation and TNF-α production with IC50 values of 11 nM and 7 nM, respectively. QNZ (EVP4593) is a neuroprotective inhibitor of SOC channels.

Synonyms: EVP4593; CAY10470

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of QNZ

CAS No. :545380-34-5
Formula : C22H20N4O
M.W : 356.42
SMILES Code : NC1=CC2=C(NCCC3=CC=C(OC4=CC=CC=C4)C=C3)N=CN=C2C=C1
Synonyms :
EVP4593; CAY10470
MDL No. :MFCD06411436
InChI Key :IBAKVEUZKHOWNG-UHFFFAOYSA-N
Pubchem ID :509554

Safety of QNZ

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • TNF-α

    TNF-α, IC50:7 nM

  • NF-κB

    NF-κB, IC50:11 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
macrophages 20 nM to study the effect of QNZ on the NFκB signaling pathway in macrophages PMC5591335
BM-LCs 100 ng/ml 3 h IL-38 did not directly affect the migration of BM-LCs PMC11186352
BM-LCs 100 ng/ml 24 h IL-38 pretreatment significantly increased the migration of BM-LCs under CCL21 stimulation PMC11186352
SW620 cells 10 nM QNZ decreased the expression of CCL20 in SW620 cells PMC6688336
DLD-1 cells 10 nM QNZ decreased the expression of CCL20 in DLD-1 cells PMC6688336
BMDCs 80 μg/mL 22 h To verify whether QNZ affects BMDC maturation by inhibiting the NF-κB signaling pathway. The results showed that pretreatment with QNZ significantly inhibited KK2DP7-induced BMDC maturation. PMC10214225
BV2 microglial cells 10 µM 24 h QNZ significantly suppressed the inhibitory effect of 2.5 µM EC on the expression of iNOS PMC6766924
HaCaT cells 5 μM QNZ alone significantly inhibited cell proliferation and induced apoptosis, and no additional effect on inhibiting cell proliferation or inducing apoptosis was observed when combined with BIX01294. PMC10517171

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice DNFB-induced AD model transdermal administration 2 mg/kg from day 6 until the end of modelling QNZ alleviated DNFB-induced AD symptoms by inhibiting the NF-κB signaling pathway PMC11186352

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.03mL

2.81mL

1.40mL

28.06mL

5.61mL

2.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories